1271 Avenue of the Americas |New York, NY 10020
June 24, 2022
The Board of Directors
Adial Pharmaceuticals, Inc.
1001 Research Park Blvd., Suite 100
Charlottesville, VA 22911
Re: Registration Statement on Form S-1 (File No. 333-229615)
Dear Ladies and Gentlemen:
We have acted as U.S. securities counsel to Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), of a Post-Effective Amendment to the Registration Statement on Form S-1 (File No. 333-229615) (as amended through the date hereof, the “Registration Statement”) relating to the registration by the Company of an aggregate of 2,133,750 shares (the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), underlying warrants (the “Warrants”) issued to investors in the Company’s public offering that closed on February 25, 2019. The Warrants and the Warrant Shares were registered and remain unsold under the Company’s Registration Statement, which was initially declared effective by the Commission on February 20, 2019, and the concurrent post-effective amendment to the Registration Statement. The Warrants and the Warrant Shares were initially sold by the Company pursuant to an underwriting agreement (the “Underwriting Agreement”), dated February 20, 2019, entered into by and between the Company and Maxim Group LLC and Joseph Gunnar & Co., LLC, as representatives of the several underwriters named therein, the form of which has been filed as Exhibit 1.1 to the Registration Statement.
In our capacity as counsel to the Company, we have examined the original or certified copies of such records of the Company and such agreements, certificates of public officials, certificates of officers or representatives of the Company and others, and such other documents as we deem relevant and necessary as a basis for the opinions hereinafter expressed, including, but not limited to, the Warrants and the Underwriting Agreement. In such examination we have assumed the genuineness of all signatures on original documents and the conformity to original documents of all copies submitted to us as conformed or photostat copies. As to various questions of fact material to such opinions, we have relied upon statements or certificates of officials and representatives of the Company and others.
Based upon the foregoing, it is our opinion that the Warrant Shares issuable upon exercise of the Warrants, when sold, paid for and issued upon exercise of the Warrants and upon receipt of payment of the exercise price thereof, if applicable, in accordance with the respective terms thereof, will be duly and validly issued, fully paid and non-assessable.
We are opining solely on all applicable statutory provisions of Delaware corporate law, including the rules and regulations underlying those provisions, all applicable provisions of the Delaware Constitution and all applicable judicial and regulatory determinations. This opinion is limited to the laws of the State of Delaware as in effect on the date hereof and we express no opinion with respect to the laws of any other jurisdiction. We hereby consent to the filing of this opinion as an Exhibit to the Registration Statement. We also hereby consent to the use of our name as your counsel under “Legal Matters” in the Prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby concede that we come within the categories of persons whose consent is required by the Act or the General Rules and Regulations promulgated thereunder.
|Very truly yours,|
|/s/ BLANK ROME|
|BLANK ROME LLP|